文献速递血液净化与透析

腹腔内万古霉素联合口服莫西沙星或腹腔内头孢他啶治疗腹膜透析相关腹膜炎:一项随机对照先导研究

Intraperitoneal Vancomycin Plus Either Oral Moxifloxacin or Intraperitoneal Ceftazidime for the Treatment of Peritoneal Dialysis-Related Peritonitis: A Randomized Controlled Pilot Study.
PubMed 文献 · Am J Kidney Dis · 2016-12-24

该随机对照先导研究纳入80例腹膜透析相关腹膜炎患者,比较腹腔内万古霉素联合口服莫西沙星与联合腹腔内头孢他啶的疗效。两组腹膜炎完全缓解率分别为78%和80%(OR 0.86,95%CI 0.30-2.52,P=0.8),治疗失败率无显著差异。作者认为口服莫西沙星方案安全有效,但需更大样本试验验证。

要点

  • 两组腹膜炎完全缓解率分别为78%和80%,差异无统计学意义。
  • 治疗组与对照组分别有1例腹膜炎相关死亡和6例转血液透析。
  • 仅观察到2例轻微药物不良反应(恶心和皮疹各1例)。

核心结论

  • 该先导研究提示腹腔内万古霉素联合口服莫西沙星是安全、耐受良好、实用且有效的腹膜透析相关腹膜炎一线治疗。
  • 需要更大规模、有足够把握度的临床试验进一步验证。

研究设计与样本

  • 随机对照先导研究,来自北京大学第一医院,纳入80例腹膜透析相关腹膜炎患者,每组40例。
  • 干预组:腹腔内万古霉素1g每5天一次联合口服莫西沙星400mg每天一次;对照组:腹腔内万古霉素1g每5天一次联合腹腔内头孢他啶1g每天一次。

主要发现

  • 治疗组和对照组腹膜炎完全缓解率分别为78%和80%(OR 0.86,95%CI 0.30-2.52,P=0.8)。
  • 治疗组和对照组复发分别为3例和1例。
  • 原发性治疗失败率治疗组33% vs 对照组20%,继发性治疗失败率治疗组10% vs 对照组13%,均无显著差异。
  • 每组各有1例腹膜炎相关死亡和6例转血液透析。
  • 3个月随访期间,治疗组和对照组分别发生7次和3次连续性腹膜炎发作;仅观察到2例药物不良反应(轻度恶心和轻度皮疹各1例)。

临床怎么用

  • 作者认为腹腔内万古霉素联合口服莫西沙星可作为腹膜透析相关腹膜炎的一线治疗,但需更大规模临床试验验证。

局限性

  • 样本量相对较小,且合格率低。
  • 腹膜炎发作次数少,限制了检测组间差异的把握度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intraperitoneal administration of antibiotics is recommended as a first treatment for managing peritoneal dialysis (PD)-related peritonitis. However, the efficacy of oral administration of quinolones has not been well studied. STUDY DESIGN: Randomized controlled pilot study. SETTING & PARTICIPANTS: 80 eligible patients with PD-related peritonitis from Peking University First Hospital (40 in each arm). INTERVENTION: Intraperitoneal vancomycin, 1g, every 5 days plus oral moxifloxacin, 400mg, every day (treatment group) versus intraperitoneal vancomycin, 1g, every 5 days plus intraperitoneal ceftazidime, 1g, every day (control group). OUTCOMES: The primary end point was complete resolution of peritonitis, and secondary end points were primary or secondary treatment failure. MEASUREMENTS: PD effluent white blood cell count. RESULTS: Baseline demographic and clinical characteristics of the 2 groups were comparable. There were 24 and 22 Gram-positive organisms, 6 and 7 Gram-negative organisms, 9 and 10 culture-negative samples, and 1 and 1 fungal sample in the treatment and control groups, respectively. Complete resolution of peritonitis was achieved in 78% and 80% of cases in the treatment and control groups, respectively (OR, 0.86; 95% CI, 0.30-2.52; P=0.8). There were 3 and 1 cases of relapse in the treatment and control groups, respectively. Primary and secondary treatment failure rates were not significantly different (33% vs 20% and 10% vs 13%, respectively). In each group, there was 1 peritonitis-related death and 6 transfers to hemodialysis therapy. During the 3-month follow-up period, 7 and 3 successive episodes of peritonitis occurred in the treatment and control groups, respectively. Only 2 adverse drug reactions (mild nausea and mild rash, respectively) were observed in the 2 groups. LIMITATIONS: Sample size was relatively small and the eligibility ratio was low. Also, the number of peritonitis episodes was low, limiting the power to detect a difference between groups. CONCLUSIONS: This pilot study suggests that intraperitoneal vancomycin with oral moxifloxacin is a safe, well-tolerated, practical, and effective first-line treatment for PD-related peritonitis. Larger adequately powered clinical trials are warranted.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Xu R, Yang Z, Qu Z, et al. Intraperitoneal Vancomycin Plus Either Oral Moxifloxacin or Intraperitoneal Ceftazidime for the Treatment of Peritoneal Dialysis-Related Peritonitis: A Randomized Controlled Pilot Study. Am J Kidney Dis. 2016. PMID: 28027794. doi:10.1053/j.ajkd.2016.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。